CVS Health (CVS) is in focus after opening its first pharmacy-only, apothecary-style location in Chicago, the initial step in a plan for nearly 20 similar sites this year.
See our latest analysis for CVS Health.
At a share price of US$71.82, CVS Health has seen a 10.1% 30 day share price decline and a 10.4% year to date share price decline. Its 1 year total shareholder return of 9.7% points to longer term gains even as investors weigh new pharmacy formats against the recent legal and regulatory headlines.
If this kind of pharmacy expansion has your attention, it can be a good moment to look across healthcare for other technology driven health names using our curated list of 34 healthcare AI stocks
With CVS trading at US$71.82 alongside an indicated intrinsic discount and a sizeable gap to analyst targets, you need to ask whether sentiment has pushed the stock too low, or if the market already reflects its future growth.
Most Popular Narrative: 30.9% Undervalued
According to one widely followed narrative, CVS Health's fair value of $104.01 sits well above the last close at $71.82, which puts a spotlight on the assumptions behind that gap.
CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connected with its Medicare and Individual Exchange businesses and a $1.2 billion restructuring charge for store closures. The result has been increasing uncertainty, thanks in part to leadership changes and rising medical costs, with investors questioning whether CVS can make the shift from retail to a healthcare model. The recent drop in the stock reflects the skepticism and cautious optimism of investors as the business faces pressure to increase operating income while checking the rise in expenses in the Health Care Benefits segment.
To understand what sits behind that valuation gap, this narrative focuses on earnings power, revenue growth in health benefits, and potential margin repair. The mix of restructuring, membership trends, and long term cash flow assumptions matters more here than short term price moves.
Result: Fair Value of $104.01 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be hit if medical costs stay elevated for longer or if the US$2b restructuring and acquisitions fail to deliver expected efficiencies.
Find out about the key risks to this CVS Health narrative.
Another View on CVS Health's Valuation
While the popular narrative leans on discounted cash flows, the current P/E of 51.7x tells a very different story. That is higher than the US Healthcare average of 22.8x, the peer average of 18.2x, and even above a fair ratio of 41.7x. This points to valuation risk if earnings do not improve as expected. Which lens do you trust more when numbers conflict like this?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on value and sentiment running both hot and cold, it helps to move quickly and check the underlying data yourself. To see how the risks and potential upsides line up, start by weighing these 3 key rewards and 4 important warning signs.
Looking for more investment ideas?
If CVS has sharpened your focus on where to put fresh capital next, do not stop here. Let the data surface a few more candidates worth your time.
- Target consistent value by scanning companies that currently look mispriced using our 58 high quality undervalued stocks
- Prioritise resilience first and review stocks screened for stronger balance sheets and fundamentals with the solid balance sheet and fundamentals stocks screener (39 results)
- Hunt for underfollowed potential and see what stands out in our screener containing 25 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com